Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $30M
Founded date: 2003
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Hercules C... | htgc.com |
| - | Bessemer V... | bvp.com |
| - | Lightstone... | lightstone... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.12.2011 | - | $30M | - |
Mentions in press and media 20
| Date | Title | Description | Source |
| 01.10.2021 | Why the autopsy of Zoom’s dead $14.7 billion deal matters | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 01.10.2021 | Why the autopsy of Zoom’s dead $14.7 billion deal matters | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 30.09.2021 | Merck to buy Acceleron Pharma in deal valued at $11.5 billio... | Merck & Co. agreed to buy Acceleron Pharma Inc. in a deal valuing the drugmaker at $11.5 billion... | business-s... |
| 18.06.2021 | ACCELERON PHARMA INC. Acceleron Pharma : Reblozyl was gener... | Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patien... | marketscre... |
| 29.03.2019 | bluebird’s gene therapy gets nod from EMA panel – for real t... | Shares of bluebird on the Nasdaq opened up about 2 percent following the news. SVB Leerink analyst M... | medcitynew... |
| 20.03.2019 | Flagship Pioneering raises $824M in new fund | “With each year of company origination, as we honed our pioneering approach, we have steadily increa... | medcitynew... |
| 03.01.2018 | A better approach to growth factors? Scholar Rock raise... | Scholar Rock, a biotech based of out Cambridge, MA, just got a $47 million infusion of cash to ... | endpts.com... |
| 26.03.2015 | Flagship Ventures raises $537M in new fund; plans to launch ... | The company’s previous fund was $269 million. Some of its more successful exits during this biotech ... | medcitynew... |
| 26.03.2014 | The 2014 Midas List: Fewer New Names And More Explosive Exit... | For the third straight year, the number of newcomers to the Midas List has dropped. From 38 new name... | forbes.com... |
| 01.11.2013 | OrbiMed closes its largest VC fund, predicts rebound in heal... | Looking back 5 to 6 years, healthcare venture capital funds raised $7.8 billion, but last year they ... | medcitynew... |
Show more